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Abstract
Background—Invasive fungal diseases are important causes of morbidity and mortality. Clarity
and uniformity in defining these infections are important factors in improving the quality of clinical
studies. A standard set of definitions strengthens the consistency and reproducibility of such studies.
Methods—After the introduction of the original European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances
in diagnostic technology and the recognition of areas in need of improvement led to a revision of
this document. The revision process started with a meeting of participants in 2003, to decide on the
process and to draft the proposal. This was followed by several rounds of consultation until a final
draft was approved in 2005. This was made available for 6 months to allow public comment, and
then the manuscript was prepared and approved.
Results—The revised definitions retain the original classifications of “proven,” “probable,” and
“possible” invasive fungal disease, but the definition of “probable” has been expanded, whereas the
scope of the category “possible” has been diminished. The category of proven invasive fungal disease
can apply to any patient, regardless of whether the patient is immunocompromised, whereas the
probable and possible categories are proposed for immunocompromised patients only.
Conclusions—These revised definitions of invasive fungal disease are intended to advance clinical
and epidemiological research and may serve as a useful model for defining other infections in high-
risk patients.
In 2002, a consensus group of the European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group (EORTC) and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (MSG) published standard definitions
for invasive fungal infections for clinical and epidemiological research [1]. These definitions
were developed to facilitate the identification of reasonably homogeneous groups of patients
for clinical and epidemiologic research, to help design clinical trials to evaluate new drugs and
management strategies, and, last but not least, to foster communication between international
researchers. The definitions assigned 3 levels of probability to the diagnosis of invasive fungal
infection that develops in immunocompromised patients with cancer and in hematopoietic stem
cell transplant recipients—namely, “proven,” “probable,” and “possible” invasive fungal
infection. The definitions established a formal framework for defining invasive fungal infection
with a variable certainty of diagnosis. Proven invasive fungal infection required only that a
fungus be detected by histological analysis or culture of a specimen of tissue taken from a site
of disease; in the case of Cryptococcus neoformans, detection of capsular antigen in CSF or a
positive result of an India ink preparation of CSF was considered sufficient to establish a
diagnosis of proven cryptococcosis. By contrast, probable and possible invasive fungal
infections hinged on 3 elements—namely, a host factor that identified the patients at risk,
clinical signs and symptoms consistent with the disease entity, and mycological evidence that
encompassed culture and microscopic analysis but also indirect tests, such as antigen detection.
These EORTC/MSG Consensus Group definitions have been used in major trials of antifungal
drug efficacy, in strategy trials [2–6], for the formulation of clinical practice guidelines [7], for
validation of diagnostic tests [8–13], and for performance of epidemiologic studies [14].
The previously published definitions were not without their shortcomings. For instance, the
original category of possible invasive fungal infection allowed too many dubious cases to be
included, particularly those involving neutropenia, nonspecific pulmonary infiltrates, and
persistent fever refractory to broad-spectrum antibiotics but with no evidence of invasive fungal
infection [15]. These cases may represent patients at higher risk of invasive fungal infection
but are quite different from the cases, also defined as possible cases, for which more specific
pulmonary abnormalities, such as a halo or air-crescent sign characteristic of invasive
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aspergillosis, were present. Indeed, the definitions were modified to allow enrollment of similar
cases into clinical trials, because they are considered to represent likely invasive fungal disease
even without supporting mycological evidence [2,16]. This pragmatic approach solved the
problem of recruitment of representative cases, but it clearly highlighted the need to refine
further the definitions, to distinguish dubious cases from the more likely cases when
mycological evidence was not forthcoming. The growing body of evidence regarding the value
of high-resolution CT of chest and abdomen [17] and of indirect diagnostic tests—such as the
detection of galactomannan in body fluids other than serum and plasma, of β-D-glucan in serum,
and of fungal DNA in body fluids by PCR—provided additional incentive to review the
definitions [18,19]. The original definitions were also restricted to patients with cancer and to
recipients of hematopoietic stem cell transplants; however, invasive fungal infections are
known to affect other populations, including recipients of solid-organ transplants and patients
with primary immunodeficiencies (e.g., chronic granulomatous disorder) [20,21]. Finally, it
was considered appropriate to explore the possibility of formulating specific criteria for
diseases caused by less common fungal pathogens.
Revision Process
The EORTC/MSG Consensus Group met in Chicago, Illinois, on 14 September 2003 during
the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) and included 13 members from the EORTC and 17 from the MSG. J. Powers also
participated for the US Food and Drug Administration (FDA), and there were 5 observers from
4 pharmaceutical companies (J. Rex [Astra Zeneca], C. Sable [Merck], M. Bresnik [Gilead],
and G. Triggs and A. Baruch [Pfizer]). B.d.P. and T.J.W. were confirmed as joint chairs, and
J.P.D. was designated as secretary for the group. Three subcommittees were appointed to
prepare proposals for mold infection, candidiasis, and endemic mycoses. The proposals were
collated by the secretary, who integrated them into a general framework. They were then
circulated by electronic mail to all group members. The ensuing comments again were centrally
combined for a subsequent round of electronic consultation. The remaining issues that appeared
difficult to solve by the electronic route were addressed in open meetings during the 15th
European Congress of Clinical Microbiology and Infectious Disease in Copenhagen, Denmark,
and the 45th Annual ICAAC in Washington, DC. A majority vote was decisive when a
consensus among the members could not be achieved. The final draft was made available to
the wider community for comment at the Doctor Fungus Web site [22] and The Aspergillus
Web site [23]. Thereafter, the manuscript was prepared and was circulated among all group
members for their final approval.
At the first meeting, all group members agreed to the need to refine and revise the definitions.
It was also agreed unanimously that the definition set should remain easily reproducible and
should offer the opportunity for a reasonable comparison of future data sets with data sets that
had been collected in clinical trials that involved patients with proven and probable invasive
fungal infections according to the original definitions. Finally, the group set out to reexamine
the feasibility of using the definitions for treatment purposes, to devise a means of extending
their applicability to other patient groups, to review the relevance of the findings obtained from
studies based on the definitions for clinical practice, and to attempt to incorporate all the
available laboratory tests and imaging techniques into the definitions.
Revised Definitions
The term “invasive fungal disease” (IFD) was adopted to reflect more accurately the notion
that we are dealing with a disease process caused by fungal infection. An adequate diagnostic
evaluation of the infectious disease process, to exclude an alternative etiology, was deemed to
be a necessary prerequisite to classify it as an IFD. The group reaffirmed that the definitions
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should be used only to assist in research and that the integrity of the original definitions with
the classifications of proven, probable, and possible IFD would be preserved (tables 1–3).
Infections caused by Pneumocystis jiroveci are not included. The criteria for proven and
probable IFD (tables 1 and 2) were modified to reflect advances in indirect tests, whereas the
category of possible IFD (table 3) was revised to include only cases that are highly likely to
be caused by a fungal etiology, although mycological evidence is lacking. Hence, the
definitions of probable and possible IFD were based on the same 3 elements as were the original
definitions: host factors, clinical manifestations, and mycological evidence.
Host factors are not synonymous with risk factors but are characteristics by which individuals
predisposed to acquire IFD can be recognized. Consequently, the presence of fever was
removed as a host factor because it represents a clinical feature, not a host factor, and is
nonspecific for IFD. The host factors were extended to receipt of a solid-organ transplant,
hereditary immunodeficiencies, connective tissue disorders, and receipt of immunosuppressive
agents—for example, corticosteroids or T cell immunosuppressants, such as calcineurin
inhibitors, anti–TNF-α drugs, anti-lymphocyte antibodies, or purine analogues. The distinction
between “minor” and “major” clinical criteria was abandoned in favor of more-characteristic
and objectively verifiable evidence, such as the findings on medical imaging that indicated a
disease process consistent with IFD by use of a standardized glossary of definitions. For
example, in the case of chest CT imaging to categorize pulmonary lesions, the vast majority
of immunocompromised patients with invasive pulmonary aspergillosis have focal rather than
diffuse pulmonary infiltrates and present with at least 1 macronodule, with or without a halo
sign [24]. These infections can also manifest as wedge-shaped infiltrates and segmental or
lobar consolidation. Although none of the imaging findings is pathognomonic for IFD, the
observation that, in the appropriate patient population, the outcome of antifungal therapy did
not differ between febrile patients with nodular lesions and patients with mycological evidence
of an IFD supports the use of this clinical criterion [17]. A similar consideration applies to
patients with lesions on CT or ultrasound that are regarded as typical for chronic disseminated
candidiasis. In the original definitions, patients with such lesions were defined as having
probable hepatosplenic candidiasis without any need for mycological support. In the revised
definitions, such cases are classified as possible IFD, thereby retaining the consistency of the
definitions and preserving the distinction between probable IFD and possible IFD. For a patient
with appropriate host factors and clinical evidence of pulmonary disease, bronchoalveolar
lavage fluid that yields Aspergillus, Zygomycetes, Fusarium, or Scedosporium species or other
pathogenic molds would constitute mycological support and would allow the case to be
classified as probable pulmonary IFD.
As with the original definitions, indirect tests were considered for inclusion only if they were
validated and standardized. Furthermore, because commercial tests for diagnostic use had to
provide criteria for interpretation to gain approval, it was decided to rely entirely on the
thresholds recommended by the manufacturer. On the basis of recent studies, the Platelia
Aspergillus galactomannan EIA could be applied to CSF and bronchoalveolar lavage fluid, as
well as plasma and serum. The β-D-glucan assay also was included as a marker for probable
IFD, because this test detects other species of fungi besides Aspergillus, and a commercial test
for it (Fungitell assay; Associates of Cape Cod) has been approved by the FDA. By contrast,
molecular methods of detecting fungi in clinical specimens, such as PCR, were not included
in the definitions because there is as yet no standard, and none of the techniques has been
clinically validated.
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The Categories
Proven IFD
There was general agreement that the category of proven IFD should be retained, requiring
proof of IFD by demonstration of fungal elements in diseased tissue for most conditions (table
1). Revisions were made to this category to reflect advances in indirect assays that are highly
specific for the infection being detected. By its very nature, this category is likely to be valid
irrespective of host factors or clinical features. Individual IFD entities—for example, proven
aspergillosis—require culture and identification. Failing this, the disease is designated as
proven mold IFD (table 1). The histological appearance of the endemic dimorphic fungi,
Histoplasma capsulatum, as small intracellular budding yeasts; Coccidioides species as
spherules; Paracoccidioides brasiliensis as large yeasts with multiple daughter yeasts in a
“pilot-wheel configuration”; and Blastomyces dermatitidis as thick-walled, broad-based
budding yeasts is sufficiently distinctive to permit a definitive diagnosis (table 3). H.
capsulatum variety capsulatum resembles Candida glabrata or Leishmania species in tissue
but can be distinguished from them by characteristic histological features of granulomatous
inflammation in histoplasmosis in some patient groups and by staining with silver, which shows
staining for the fungi but not for Leishmania species.
The category of proven IFD was modified to reflect advances in our understanding of
Coccidioides serological characteristics. Consequently, the presence of coccidioidal antibody
in CSF was considered to be sufficient to fulfill the criteria for proven coccidioidomycosis.
Similarly, the presence of capsular antigen in CSF was considered to be sufficiently distinctive
to establish a diagnosis of disseminated cryptococcosis [25]. Urinary Histoplasma antigen
supports a diagnosis of probable endemic mycosis, in conjunction with appropriate host and
clinical criteria (table 3), but cannot be considered sufficient evidence of proven
histoplasmosis, because Histoplasma antigen is also found in urine and serum of patients with
coccidioidomycosis and blastomycosis [26].
Probable IFD
Cases of probable IFD require that a host factor, clinical features, and mycological evidence
be present, as outlined in tables 2 and 3.
Possible IFD
The category of possible IFD was retained but was defined more strictly to include only those
cases with the appropriate host factors and with sufficient clinical evidence consistent with
IFD but for which there was no mycological support (table 2). However, this category was not
considered appropriate for endemic mycosis, because host factors and clinical features are not
sufficiently specific and because such cases would be of value too limited to include in clinical
trials, epidemiological studies, or evaluations of diagnostic tests.
Comments
Implications of the revised category of possible IFD
After enrollment into an interventional or diagnostic study, every effort should be made to
upgrade the certainty of diagnosis for patients with possible IFD to the category of proven or
probable IFD. These definitions may be applied at different times during the period of risk.
For example, although a case might not meet the definition of possible, probable, or proven
IFD at the beginning of a period of high risk, during which prophylaxis is given, the case may
continue to evolve, such that the criteria may be met later.
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The overrepresentation of dubious cases that resulted from the application of the original
definitions made it imperative to redress the balance and to capture more patients with a higher
probability of IFD while excluding patients who are unlikely to have invasive mycosis. Some
members even argued that the category of possible IFD, as defined in the original set of
definitions, should be abolished altogether. However, such a decision would reduce
dramatically the number of candidates eligible for clinical studies of fungal pneumonia, making
randomized trials nearly impossible to conduct. The corollary of retaining a better-defined
category of possible IFD, to reduce the number of doubtful cases, was that greater emphasis
was placed on mycological evidence for the categories of proven and probable IFD. This allows
the category of possible IFD to be reserved for clinical manifestations fully consistent with
fungal etiology but for which there is no mycological evidence available, although a reasonable
attempt has been made to exclude an alternative etiology.
Non–culture-based diagnostic tests
There was much discussion about indirect mycological tests, especially assays for detection of
antigen and β-D-glucan. Since the first definitions were published [1], the FDA has approved
the Aspergillus galactomannan EIA and, more recently, the assay for β-D-glucan, on the grounds
that they were standardized, were validated, are available, and are fit to convey useful
information [8,19,27]. However, controversy arose about the interpretation of the index for the
galactomannan assay, which was originally set at 1.5 and was applied in Europe but which was
lowered to 0.5 after review by the FDA. This cutoff value has been shown recently to improve
the overall performance of the test for adult hematology patients [28]. Because the issue
remains contentious, the decision was made to place the onus on the manufacturers of
commercial tests and to adopt whatever threshold values they recommend.
We had hoped that nucleic acid–detection tests, such as PCR, would have improved enough
to incorporate the results of these tests into the definitions. However, standardization and
validation have not yet been attained for these platforms.
Limitations of the revised definitions
The revised definitions apply to immunocompromised patients but not necessarily to critically
ill patients in the intensive care unit who, nonetheless, may develop possible or probable IFD
[29]. The group recognized this as an omission but was unable to find a sufficient basis for
identifying the appropriate host factors, even though there may be mycological evidence, such
as recovery of Aspergillus species from bronchial secretions or a positive β-D-glucan test result.
The group, therefore, concluded that the body of evidence supporting a diagnosis other than
proven IFD is not sufficiently mature at present.
The definitions are not a substitute for complete clinicopathologic descriptions and
classifications of IFD, as have been published recently for aspergillosis [21]. The failure to
meet the criteria for IFD does not mean that there is no IFD, only that there is insufficient
evidence to support the diagnosis. This is the most compelling reason for not employing these
definitions in daily clinical practice.
We anticipate that the field of diagnosis will continue to evolve, so that there will come a time
when the definitions may be formally evaluated for their sensitivity and specificity. Until then,
additional revisions of the present set of definitions are likely, but they should be contemplated
carefully. The words and phrases chosen here were selected on the basis of extensive debate
and discussion. Seemingly, slight changes may have unexpectedly profound consequences in
the design, implementation, and interpretation of clinical trials.
De Pauw et al. Page 7
Clin Infect Dis. Author manuscript; available in PMC 2009 April 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
These revised definitions of IFD categories are intended to advance clinical and
epidemiological research and, as such, may serve as a useful model for defining other infections
in high-risk patients. The definitions are not meant to be used to guide clinical practice but
must be applied consistently if they are to continue to achieve their primary goal of fostering
communication, furthering our understanding of the epidemiology and evolution of IFD, and
facilitating our ability to test the efficacy of therapeutic regimens and strategies.
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Table 2
Criteria for probable invasive fungal disease except for endemic mycoses
Host factorsa
 Recent history of neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days) temporally related to the onset of fungal disease
 Receipt of an allogeneic stem cell transplant
 Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/
day of prednisone equivalent for >3 weeks
 Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-α blockers, specific monoclonal antibodies (such as
alemtuzumab), or nucleoside analogues during the past 90 days
 Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)
Clinical criteriab
 Lower respiratory tract fungal diseasec
  The presence of 1 of the following 3 signs on CT:
   Dense, well-circumscribed lesions(s) with or without a halo sign
   Air-crescent sign
   Cavity
 Tracheobronchitis
  Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
 Sinonasal infection
  Imaging showing sinusitis plus at least 1 of the following 3 signs:
   Acute localized pain (including pain radiating to the eye)
   Nasal ulcer with black eschar
   Extension from the paranasal sinus across bony barriers, including into the orbit
 CNS infection
  1 of the following 2 signs:
   Focal lesions on imaging
   Meningeal enhancement on MRI or CT
 Disseminated candidiasisd
  At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:
   Small, target-like abscesses (bull's-eye lesions) in liver or spleen
   Progressive retinal exudates on ophthalmologic examination
Mycological criteria
 Direct test (cytology, direct microscopy, or culture)
  Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
   Presence of fungal elements indicating a mold
   Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
 Indirect tests (detection of antigen or cell-wall constituents)e
  Aspergillosis
   Galactomannan antigen detected in plasma, serum, bronchoalveolar lavage fluid, or CSF
  Invasive fungal disease other than cryptococcosis and zygomycoses
   β-D-glucan detected in serum
NOTE. Probable IFD requires the presence of a host factor, a clinical criterion, and a mycological criterion. Cases that meet the criteria for a host factor
and a clinical criterion but for which mycological criteria are absent are considered possible IFD.
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a
Host factors are not synonymous with risk factors and are characteristics by which individuals predisposed to invasive fungal diseases can be recognized.
They are intended primarily to apply to patients given treatment for malignant disease and to recipients of allogeneic hematopoietic stem cell and solid-
organ transplants. These host factors are also applicable to patients who receive corticosteroids and other T cell suppressants as well as to patients with
primary immunodeficiencies.
b
Must be consistent with the mycological findings, if any, and must be temporally related to current episode.
c
Every reasonable attempt should be made to exclude an alternative etiology.
d
The presence of signs and symptoms consistent with sepsis syndrome indicates acute disseminated disease, whereas their absence denotes chronic
disseminated disease.
e These tests are primarily applicable to aspergillosis and candidiasis and are not useful in diagnosing infections due to Cryptococcus species or
Zygomycetes (e.g., Rhizopus, Mucor, or Absidia species). Detection of nucleic acid is not included, because there are as yet no validated or standardized
methods.
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Table 3
Criteria for the diagnosis of endemic mycoses
Diagnosis and criteria
Proven endemic mycosis
 In a host with an illness consistent with an endemic mycosis, 1 of the following:
  Recovery in culture from a specimen obtained from the affected site or from blood
  Histopathologic or direct microscopic demonstration of appropriate morphologic forms with a truly distinctive appearance characteristic of
dimorphic fungi, such as Coccidioides species spherules, Blastomyces dermatitidis thick-walled broad-based budding yeasts, Paracoccidioides
brasiliensis multiple budding yeast cells, and, in the case of histoplasmosis, the presence of characteristic intracellular yeast forms in a phagocyte in a
peripheral blood smear or in tissue macrophages
  For coccidioidomycosis, demonstration of coccidioidal antibody in CSF, or a 2-dilution rise measured in 2 consecutive blood samples tested
concurrently in the setting of an ongoing infectious disease process
  For paracoccidioidomycosis, demonstration in 2 consecutive serum samples of a precipitin band to paracoccidioidin concurrently in the setting of
an ongoing infectious disease process
Probable endemic mycosis
 Presence of a host factor, including but not limited to those specified in table 2, plus a clinical picture consistent with endemic mycosis and mycological
evidence, such as a positive Histoplasma antigen test result from urine, blood, or CSF
NOTE. Endemic mycoses includes histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis, and infection due to
Penicillium marneffei. Onset within 3 months after presentation defines a primary pulmonary infection. There is no category of possible endemic mycosis,
as such, because neither host factors nor clinical features are sufficiently specific; such cases are considered to be of value too limited to include in clinical
trials, epidemiological studies, or evaluations of diagnostic tests.
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